Comparing oral Gemifloxacin and intravenous Cefotaxime for treating spontaneous bacterial peritonitis
Official title: Comparative Study Between the Efficacy of Oral Gemifloxacin and Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Run by Tanta University · NCT04168099 · Data updated 2026-11-12
This study is testing whether taking Gemifloxacin by mouth works as well as getting Cefotaxime through an IV for treating people with spontaneous bacterial peritonitis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Tanta) |
| Status | Recruiting |
| Started | December 1, 2018 |
| Main results expected | December 1, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | November 19, 2019 |
| Trial ID | NCT04168099 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with spontaneous bacterial peritonitis.
✕Probably not a fit
Patients with secondary peritonitis will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study compares the effectiveness of oral Gemifloxacin with intravenous Cefotaxime in treating patients diagnosed with spontaneous bacterial peritonitis. It aims to determine which treatment option provides better outcomes for patients suffering from this condition. The study is interventional and is conducted in a Phase 3 setting, indicating a focus on confirming efficacy and monitoring side effects in a larger patient population.
Why it matters
Potential benefit: If successful, this study could provide a more effective or convenient treatment option for patients with spontaneous bacterial peritonitis.
How similar studies have gone: Other studies have explored antibiotic treatments for spontaneous bacterial peritonitis, but the specific comparison of oral Gemifloxacin and intravenous Cefotaxime is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with spontaneous bacterial peritonitis Exclusion Criteria: * secondary peritonitis
Where it's running
-
Sherief Abd-Elsalam
Tanta, Egypt Recruiting
Study contacts
- Principal investigator: Hala Shaaban El Gendy, Msc — Tanta University - Faculty of Medicine
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Is routine follow-up paracentesis needed after starting antibiotics for SBP in cirrhosis?
We’re testing whether doing a follow-up paracentesis at 48 hours after starting antibiotics changes outcomes for people with spontaneous bacterial peritonitis due to liver cirrhosis.
-
Comparing Norfloxacin with Itopride to Norfloxacin alone for preventing infections in liver disease patients
This study tests if adding Itopride to Norfloxacin can better prevent infections in liver disease patients who have had a previous infection.
-
Nitazoxanide for spontaneous bacterial peritonitis in adults with cirrhosis
This study tests whether nitazoxanide can help adults with cirrhosis and spontaneous bacterial peritonitis when compared to placebo.
-
N-Acetylcysteine to help manage spontaneous bacterial peritonitis in adults with cirrhosis
Aimed at adults with cirrhosis and spontaneous bacterial peritonitis to see if adding N-acetylcysteine to standard therapy helps improve outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.